1. Home
  2. HBT vs EVO Comparison

HBT vs EVO Comparison

Compare HBT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HBT

HBT Financial Inc.

HOLD

Current Price

$26.56

Market Cap

904.3M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.50

Market Cap

821.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBT
EVO
Founded
1920
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.3M
821.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
HBT
EVO
Price
$26.56
$2.50
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$29.25
$7.00
AVG Volume (30 Days)
74.2K
110.1K
Earning Date
04-20-2026
05-05-2026
Dividend Yield
3.44%
N/A
EPS Growth
7.96
N/A
EPS
2.44
N/A
Revenue
N/A
N/A
Revenue This Year
$35.73
N/A
Revenue Next Year
$7.01
$7.13
P/E Ratio
$10.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.46
$2.31
52 Week High
$29.88
$4.80

Technical Indicators

Market Signals
Indicator
HBT
EVO
Relative Strength Index (RSI) 48.68 36.10
Support Level $26.23 $2.31
Resistance Level $26.81 $3.78
Average True Range (ATR) 0.68 0.08
MACD 0.08 0.01
Stochastic Oscillator 67.36 22.51

Price Performance

Historical Comparison
HBT
EVO

About HBT HBT Financial Inc.

HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: